One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. / Vedtofte, Louise; Bahne, Emilie; Foghsgaard, Signe; Bagger, Jonatan I.; Andreasen, Camilla; Strandberg, Charlotte; Gortz, Peter M.; Holst, Jens J.; Gronbaek, Henning; Svare, Jens A.; Clausen, Tine D.; Mathiesen, Elisabeth R.; Damm, Peter; Gluud, Lise L.; Knop, Filip K.; Vilsboll, Tina.

In: Journal of Clinical Medicine, Vol. 9, No. 10, 3213, 2020.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Vedtofte, L, Bahne, E, Foghsgaard, S, Bagger, JI, Andreasen, C, Strandberg, C, Gortz, PM, Holst, JJ, Gronbaek, H, Svare, JA, Clausen, TD, Mathiesen, ER, Damm, P, Gluud, LL, Knop, FK & Vilsboll, T 2020, 'One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial', Journal of Clinical Medicine, vol. 9, no. 10, 3213. https://doi.org/10.3390/jcm9103213

APA

Vedtofte, L., Bahne, E., Foghsgaard, S., Bagger, J. I., Andreasen, C., Strandberg, C., Gortz, P. M., Holst, J. J., Gronbaek, H., Svare, J. A., Clausen, T. D., Mathiesen, E. R., Damm, P., Gluud, L. L., Knop, F. K., & Vilsboll, T. (2020). One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. Journal of Clinical Medicine, 9(10), [3213]. https://doi.org/10.3390/jcm9103213

Vancouver

Vedtofte L, Bahne E, Foghsgaard S, Bagger JI, Andreasen C, Strandberg C et al. One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. Journal of Clinical Medicine. 2020;9(10). 3213. https://doi.org/10.3390/jcm9103213

Author

Vedtofte, Louise ; Bahne, Emilie ; Foghsgaard, Signe ; Bagger, Jonatan I. ; Andreasen, Camilla ; Strandberg, Charlotte ; Gortz, Peter M. ; Holst, Jens J. ; Gronbaek, Henning ; Svare, Jens A. ; Clausen, Tine D. ; Mathiesen, Elisabeth R. ; Damm, Peter ; Gluud, Lise L. ; Knop, Filip K. ; Vilsboll, Tina. / One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. In: Journal of Clinical Medicine. 2020 ; Vol. 9, No. 10.

Bibtex

@article{803706d89787420aaa7272318800a41d,
title = "One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial",
abstract = "Prior gestational diabetes mellitus (pGDM) is associated with increased risk of nonalcoholic fatty liver disease (NAFLD). Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists has shown beneficial effects in NAFLD patients. We evaluated the effect of the GLP-1 analogue liraglutide on NAFLD features in women with pGDM. Eighty-two overweight/obese, nondiabetic women with pGDM were included. We performed abdominal ultrasound, transient elastography with controlled attenuation parameter (CAP), and blood sampling at baseline and after 1 year. Thirty-seven women were randomized to liraglutide (1.8 mg once-daily) and 45 to placebo. Based on the ultrasound scan, 18 women (22%) had ultrasound-verified NAFLD at baseline and of these, 10 (56%) received liraglutide treatment. After 1 year, eight participants no longer had steatosis, four in each treatment group. The number of participants who developed NAFLD was similar in the two treatment groups; five in the liraglutide group and six in the placebo group (p = 0.74). Compared to placebo, liraglutide reduced the CAP-assessed intrahepatic fat content (-28 (-44;-11) vs. 2 (-13;18) dB/m, p 0.01) and body weight (-4.7 (-6.4;-2.9) vs. -1.4 (-3;0.3) kg, p 0.01). One-year's liraglutide treatment had no effect on the presence of ultrasound-diagnosed NAFLD in overweight/obese nondiabetic women with pGDM, but reduced body weight and steatosis assessed by transient elastography with CAP.",
keywords = "gestational diabetes mellitus, fatty liver, GLP-1 analogue, GLP-1 receptor agonist, hepatic fat, liraglutide, NAFLD, ATTENUATION PARAMETER CAP, MAGNETIC-RESONANCE, JAPANESE PATIENTS, ADIPOSE-TISSUE, STEATOSIS, INFLAMMATION, THERAPY, STEATOHEPATITIS, EPIDEMIOLOGY, ASSOCIATION",
author = "Louise Vedtofte and Emilie Bahne and Signe Foghsgaard and Bagger, {Jonatan I.} and Camilla Andreasen and Charlotte Strandberg and Gortz, {Peter M.} and Holst, {Jens J.} and Henning Gronbaek and Svare, {Jens A.} and Clausen, {Tine D.} and Mathiesen, {Elisabeth R.} and Peter Damm and Gluud, {Lise L.} and Knop, {Filip K.} and Tina Vilsboll",
year = "2020",
doi = "10.3390/jcm9103213",
language = "English",
volume = "9",
journal = "Journal of Clinical Medicine",
issn = "2077-0383",
publisher = "M D P I AG",
number = "10",

}

RIS

TY - JOUR

T1 - One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial

AU - Vedtofte, Louise

AU - Bahne, Emilie

AU - Foghsgaard, Signe

AU - Bagger, Jonatan I.

AU - Andreasen, Camilla

AU - Strandberg, Charlotte

AU - Gortz, Peter M.

AU - Holst, Jens J.

AU - Gronbaek, Henning

AU - Svare, Jens A.

AU - Clausen, Tine D.

AU - Mathiesen, Elisabeth R.

AU - Damm, Peter

AU - Gluud, Lise L.

AU - Knop, Filip K.

AU - Vilsboll, Tina

PY - 2020

Y1 - 2020

N2 - Prior gestational diabetes mellitus (pGDM) is associated with increased risk of nonalcoholic fatty liver disease (NAFLD). Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists has shown beneficial effects in NAFLD patients. We evaluated the effect of the GLP-1 analogue liraglutide on NAFLD features in women with pGDM. Eighty-two overweight/obese, nondiabetic women with pGDM were included. We performed abdominal ultrasound, transient elastography with controlled attenuation parameter (CAP), and blood sampling at baseline and after 1 year. Thirty-seven women were randomized to liraglutide (1.8 mg once-daily) and 45 to placebo. Based on the ultrasound scan, 18 women (22%) had ultrasound-verified NAFLD at baseline and of these, 10 (56%) received liraglutide treatment. After 1 year, eight participants no longer had steatosis, four in each treatment group. The number of participants who developed NAFLD was similar in the two treatment groups; five in the liraglutide group and six in the placebo group (p = 0.74). Compared to placebo, liraglutide reduced the CAP-assessed intrahepatic fat content (-28 (-44;-11) vs. 2 (-13;18) dB/m, p 0.01) and body weight (-4.7 (-6.4;-2.9) vs. -1.4 (-3;0.3) kg, p 0.01). One-year's liraglutide treatment had no effect on the presence of ultrasound-diagnosed NAFLD in overweight/obese nondiabetic women with pGDM, but reduced body weight and steatosis assessed by transient elastography with CAP.

AB - Prior gestational diabetes mellitus (pGDM) is associated with increased risk of nonalcoholic fatty liver disease (NAFLD). Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists has shown beneficial effects in NAFLD patients. We evaluated the effect of the GLP-1 analogue liraglutide on NAFLD features in women with pGDM. Eighty-two overweight/obese, nondiabetic women with pGDM were included. We performed abdominal ultrasound, transient elastography with controlled attenuation parameter (CAP), and blood sampling at baseline and after 1 year. Thirty-seven women were randomized to liraglutide (1.8 mg once-daily) and 45 to placebo. Based on the ultrasound scan, 18 women (22%) had ultrasound-verified NAFLD at baseline and of these, 10 (56%) received liraglutide treatment. After 1 year, eight participants no longer had steatosis, four in each treatment group. The number of participants who developed NAFLD was similar in the two treatment groups; five in the liraglutide group and six in the placebo group (p = 0.74). Compared to placebo, liraglutide reduced the CAP-assessed intrahepatic fat content (-28 (-44;-11) vs. 2 (-13;18) dB/m, p 0.01) and body weight (-4.7 (-6.4;-2.9) vs. -1.4 (-3;0.3) kg, p 0.01). One-year's liraglutide treatment had no effect on the presence of ultrasound-diagnosed NAFLD in overweight/obese nondiabetic women with pGDM, but reduced body weight and steatosis assessed by transient elastography with CAP.

KW - gestational diabetes mellitus

KW - fatty liver

KW - GLP-1 analogue

KW - GLP-1 receptor agonist

KW - hepatic fat

KW - liraglutide

KW - NAFLD

KW - ATTENUATION PARAMETER CAP

KW - MAGNETIC-RESONANCE

KW - JAPANESE PATIENTS

KW - ADIPOSE-TISSUE

KW - STEATOSIS

KW - INFLAMMATION

KW - THERAPY

KW - STEATOHEPATITIS

KW - EPIDEMIOLOGY

KW - ASSOCIATION

U2 - 10.3390/jcm9103213

DO - 10.3390/jcm9103213

M3 - Journal article

C2 - 33036179

VL - 9

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

SN - 2077-0383

IS - 10

M1 - 3213

ER -

ID: 251694937